News | News By Subject | News by Disease News By Date | Search News

Multiple sclerosis (MS) News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
What a Day! Genentech (RHHBY) Lands FDA Approval for First Drug to Treat Severe Multiple Sclerosis     4/4/2017
Perrigo (PRGO) Cuts 750 Jobs, Sells MS Drug Royalties for $2.85 Billion and Loses CFO to Amgen (AMGN)     3/1/2017
This Drug Could Rattle Biogen (BIIB) and Be the Next Billion-Dollar Blockbuster for Celgene (CELG)     2/23/2017
The 7 Worst Clinical Disasters of 2016     12/27/2016
3 Reasons That Make Biogen (BIIB) the King of a Crumbling Empire     11/14/2016
Opexa Therapeutics (OPXA) Stock Tanks After Failed MS Trial, Cuts 40% Staff     11/2/2016
Teva (TEVA) Stock Plummets After Two Patents are Invalidated by Mylan (MYL)     8/25/2016
Novartis AG (NVS) Touts Phase III Data for MS Drug Siponimod     8/25/2016
Speedy Review for Genentech (RHHBY)’s OCREVUS, Action Date December 28     6/29/2016
Biogen (BIIB) Loses $8 Billion in Market Value in One Day After Failed Trial     6/8/2016
Biogen (BIIB)'s Stock Falls as MS Drug Fails to Meet Endpoints in Mid-Stage Study     6/7/2016
Why Biogen (BIIB) Needs Yet Another Multiple Sclerosis Drug     6/3/2016
FDA Approves Biogen (BIIB) and AbbVie (ABBV)'s Once-Monthly MS Drug Zinbryta     6/2/2016
MedDay Secures $38.5 Million to Push MS Drug into Phase III Trials     4/8/2016
Bay Area's XenoPort (XNPT) Snags Psoriasis and MS Deal Worth $490 Million+ from Dr. Reddy's Laboratories Ltd. (RDY)     3/28/2016

News from Around the Web
How Much Biogen (BIIB)'s Top-Selling MS Drug Sales Could Fall by 2020     4/10/2017
Could Non-Invasive Brain Stimulation With Cognitive Training Reduce MS Symptoms? New York University’s Langone Medical Center Study     3/2/2017
GW Pharma (GWPH) Is Set To Benefit As Cannabis Takes On Cancer     2/10/2017
Multiple Sclerosis Drug Triggers Severe Adverse Events, Lancet Neurology Reveals     1/20/2017
Celgene (CELG) Could Dethrone Biogen (BIIB) in Multiple Sclerosis     9/29/2016
Brain Inflammation Linked To Depression In MS Patients, King's College London Study     7/8/2016
Poor Sleep And Thinking Problems In MS Patients, University of Michigan Study     6/21/2016
Allergy Med Might Also Fight MS-Linked Eye Damage, UCSF Study     4/14/2016
Binging On Coffee May Cut Your MS Risk, Study Published In BMJ     3/7/2016
Why It Feels So Good To Scratch An Itch, Published In Proceedings Of The Entomological Society Of Washington     2/29/2016
Sun Exposure During Teen Years May Delay Onset Of MS, Copenhagen University Hospital Study     10/8/2015
Genentech (RHHBY) May Have a $5 Billion MS Blockbuster on Its Hands     9/29/2015
Low Vitamin D Linked To MS, McGill University Study     8/27/2015
Drugs Help MS Patients Create New Stem Cells To Replace Lost Brain Cells, Case Western Reserve University Study     4/22/2015
Biogen Idec (BIIB) Tests Use of Wearables to Track MS Patient Activity     3/11/2015

Press Releases
New Investigational Data On Six-Year Efficacy Of Sanofi Genzyme (SNY)’s Lemtrada (Alemtuzumab) In Multiple Sclerosis Patients Who Experienced Relapse Between Treatment Courses To Be Presented At American Academy of Neurology     4/25/2017
Novartis AG (NVS) Real-World Data At Aan Confirms Benefit Of Gilenya On Four Key Measures Of Disease Activity In Relapsing MS     4/24/2017
Atara Biotherapeutics (ATRA) Announces Positive Interim Results from Ongoing Phase I Trial of the Autologous Version of ATA188 in Patients with Primary and Secondary Progressive Multiple Sclerosis (MS) at the American Academy of Neurology Annual Meeting 2017     4/21/2017
Genentech (RHHBY) To Present New Data At AAN Reinforcing Efficacy And Safety Of Newly FDA Approved OCREVUS (Ocrelizumab) In Two Types Of Multiple Sclerosis     4/19/2017
Genentech (RHHBY) Release: Highly Anticipated Multiple Sclerosis Medicine Offers New Hope     4/13/2017
More Than 30 Presentations Of New Investigational Data From Sanofi Genzyme (SNY)’s Multiple Sclerosis Franchise To Be Featured AtAAN     4/11/2017
Teva (TEVA) Receives Positive Outcome For COPAXONE® 40 Mg/Ml 3 Times Weekly Label In Europe     4/3/2017
numares AG And Oxford University To Collaborate On Development Of Multiple Sclerosis Diagnostic Test     3/30/2017
Alkermes (ALKS) Initiates Phase III Gastrointestinal Tolerability Study Of ALKS 8700 For Treatment Of Multiple Sclerosis     3/16/2017
Could Non-Invasive Brain Stimulation With Cognitive Training Reduce MS Symptoms? New York University’s Langone Medical Center Study     3/2/2017
NYU Langone Medical Center Release: Transcranial Direct Current Stimulation Combined With Computer Games At Home Reduces Cognitive Symptoms Of Multiple Sclerosis     2/22/2017
Apitope Announces Positive ATX-MS-1467 Phase IIa Data In Relapsing Multiple Sclerosis     2/21/2017
Apitope Announces Positive ATX-MS-1467 Phase IIa Data In Relapsing Multiple Sclerosis     2/21/2017
Momenta (MNTA) Hit With a Setback After Warning Letter From the FDA     2/20/2017
Celgene (CELG) Announces Positive Results From Phase III SUNBEAM Trial Of Oral Ozanimod In Patients With Relapsing Multiple Sclerosis     2/17/2017

//-->